Cagrilintide Powder

Cagrilintide powder is a long-acting amylin analog peptide designed for research use, intended for subcutaneous injection, primarily for studies on weight management and metabolic disorders. Based on the structure of natural amylin, its half-life is extended through fatty acid linkage modification, allowing for once-weekly dosing. Its mechanism of action involves activating amylin receptors in the hindbrain, thereby enhancing satiety, delaying gastric emptying, and reducing postprandial glucagon secretion. When used in combination with GLP-1 receptor agonists, it can synergistically suppress appetite and improve glycemic control.

1. Long-lasting molecular design

This is a structurally modified amylin analog. Its core feature is the introduction of a fatty acid side chain, enabling reversible binding to albumin, thus significantly extending its half-life and supporting once-weekly dosing. This fundamentally distinguishes it from the extremely short half-life of natural amylin.

2. Unique multi-target appetite regulation mechanism

It directly activates amylin receptors in the posterior pituitary region of the hindbrain, inhibiting appetite and energy intake from multiple dimensions:

• Enhancing satiety: Directly transmitting "fullness" signals to the brain.
• Delaying gastric emptying: Prolonging the time food remains in the stomach, physically maintaining satiety.
• Inhibiting postprandial glucagon: Improving postprandial metabolic state.

This pathway is independent of the GLP-1 mechanism, providing non-overlapping metabolic regulation.

3. Natural synergistic potential with GLP-1 drugs

Because its receptor is completely different from that of GLP-1, it naturally complements GLP-1 receptor agonists such as smegglutinin in terms of mechanism. When used in combination, it can simultaneously target two key appetite regulation pathways. Clinical data show that it can produce more significant weight loss and metabolic improvement effects, laying a scientific foundation for the development of powerful compound formulations.

Finished Product Testing (Purity/Microorganisms/Heavy Metals/Residues)

This is a critical release step, comprehensively addressing "product safety" and "quality stability."

1.Purity and Structure Confirmation

• HPLC Purity: Retesting is performed using two different chromatographic systems. Purity is typically required to be no less than 95% (some may reach over 98%), ensuring the content of the main components.
• Mass Spectrometry (MS) Identification: Precise molecular weight is determined using ESI-MS or MALDI-TOF-MS. The results must be consistent with the theoretical value (deviation < ±1 Da) to confirm the correct molecular structure.

2.Microbiological Limit Testing

Total aerobic bacteria count (TAMC) and total mold and yeast count (TYMC) are determined according to pharmacopoeia methods. Specific pathogens (such as E. coli) must not be detected to ensure the biosafety of non-sterile products under recommended storage conditions.

3.Heavy Metals and Hazardous Elements

Inductively Coupled Plasma Mass Spectrometry (ICP-MS) is used to detect catalytic residues such as lead, arsenic, cadmium, and mercury, ensuring compliance with the limits specified in ICH Q3D guidelines.

4.Solvents and Water Residues

• GC-MS or GC-FID method: Detects residual organic solvents such as acetonitrile and DMF, requiring compliance with pharmacopoeia limits.
• Karl Fischer Titration: Determines the moisture content of lyophilized powders, typically controlled at a low level to ensure product stability.

1. Supply Stability and Anti-Disruption Mechanism：Deep collaborations have been established with leading domestic peptide companies such as Chengdu Shengnuo Biotechnology, possessing large-scale production technology for over 50 marketed peptide products, with single-batch output reaching the KG level. A multi-raw material backup system is also in place-a list of 2-3 qualified suppliers for key amino acid derivatives is maintained, allowing for seamless switching in case of emergencies and eliminating the risk of supply disruptions from the source.

2. End-to-End Traceability System ：We have established a batch-to-batch digital traceability system-from amino acid raw material input, solid-phase synthesis, purification (HPLC), freeze-drying to finished product delivery, every step is recorded and accompanied by third-party testing reports. Customers can trace all production and inspection records for a batch using the batch number, ensuring "traceable origin, traceable destination, and accountability."

Summary-How We Address Your Concerns:

• Supply Disruption? → Multiple Supplier Options + KG-Level Production Capacity Guarantee
• Quality Stability? → 98%~99% HPLC Purity + ISO/GMP System Certification